Loading...
•
Jun 30, 2021
Editas Q2 2021 Earnings Report
Announced second quarter 2021 results, providing business updates and highlighting progress in clinical and preclinical programs.
Key Takeaways
Editas Medicine reported its Q2 2021 results, with a net loss of $55.3 million, or $0.81 per share. The company's cash, cash equivalents, and marketable securities totaled $698.1 million as of June 30, 2021. Clinical trials for EDIT-101 and EDIT-301 are advancing, with initial clinical data for EDIT-101 planned for September 2021 and the first patient in the RUBY trial expected to be dosed by year-end.
Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10.
EDIT-101 initial clinical data planned for September 2021.
EDIT-301 RUBY trial for sickle cell disease screening patients; first patient on track to be dosed by year-end.
Strengthened leadership with appointment of Chi Li as Chief Regulatory Officer and Bruce Eaton as Chief Business Officer.
Editas
Editas
Forward Guidance
Editas Medicine is focused on advancing its pipeline, presenting clinical data, and achieving key milestones in its clinical trials and preclinical programs.
Positive Outlook
- Completing dosing of both the pediatric and the adult high-dose cohorts in the BRILLIANCE trial in the first half of 2022.
- Beginning patient dosing in the RUBY trial by the end of 2021.
- Presenting initial clinical data from the BRILLIANCE trial at RD2021 in September 2021.
- Filing an IND for EDIT-301 for the treatment of beta-thalassemia by the end of 2021.
- Advancing manufacturing capabilities for medicines.
Challenges Ahead
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials.
- Availability and timing of results from pre-clinical studies and clinical trials.
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
- Expectations for regulatory approvals to conduct trials or to market products.
- Availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements.